{"id":"W3031754935","doi":"10.1200/jco.2020.38.15_suppl.1077","title":"Preliminary efficacy data of triple-negative breast cancer cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institutes of Health","keywords":"Medicine; Olaparib; PARP inhibitor; Internal medicine; Metastatic breast cancer; Oncology; Breast cancer; Triple-negative breast cancer; Response Evaluation Criteria in Solid Tumors; Tolerability; Clinical endpoint; Phases of clinical research; Cancer; Gastroenterology; Adverse effect; Clinical trial; Poly ADP ribose polymerase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002924292,0.001311014,0.002031586,0.0004095686,0.0004853385,0.00107885,0.0009559687,0.001192683,0.002148662],"category_scores_gemma":[0.001492201,0.0004719457,0.001180474,0.0005689982,0.0005671424,0.0005376257,0.0003504929,0.002270847,0.0009174598],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008584956,"about_ca_system_score_gemma":0.001394382,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001320707,"about_ca_topic_score_gemma":0.002988879,"domain_scores_codex":[0.9990946,0.000541297,0.00005465957,0.0000947705,0.0001060346,0.0001087195],"domain_scores_gemma":[0.998659,0.000255234,0.0002640993,0.0001388969,0.00009995126,0.0005828056],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7276028,0.05656242,0.06043788,0.000875272,0.004757716,0.0006959143,0.0003924042,0.00271863,0.05111749,0.0002044496,0.007295586,0.08733955],"study_design_scores_gemma":[0.5208193,0.3294604,0.1326117,0.00007356659,0.002598439,0.001050213,0.0001065263,0.001588698,0.004840187,0.0001583364,0.006626404,0.00006616193],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9908682,0.002183946,0.0003758847,0.0003492016,0.0000417482,0.001522152,0.002434794,0.00006233683,0.002161725],"genre_scores_gemma":[0.9840899,0.001981658,0.001371103,0.00076182,0.0001524467,0.002240749,0.007933686,0.0000423263,0.001426524],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002924292,"threshold_uncertainty_score":0.01546532,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1740430128635073,"score_gpt":0.5207388288404442,"score_spread":0.3466958159769369,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}